Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AMRI 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: AMRI 4Q

Contract revenue for the quarter, which includes Discovery Services, Development and Small Scale Manufacturing, and Large Scale Manufacturing, was $49.6 million (+22%) and $195.5 million for the year (+20%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AMRI

4Q Revenues: $56.4 million (+19%)

4Q Earnings: $3.1 million (loss of $800,000 in 4Q07)

FY Revenues: $229.3 million (+19%)

FY Earnings: $20.6 million (+130%)

Comments: Contract revenue for the quarter, which includes Discovery Services, Development and Small Scale Manufacturing, and Large Scale Manufacturing, was $49.6 million (+22%) and $195.5 million for the year (+20%). Discovery Services revenue was $13.1 million in the quarter (+13%) and $57.8 million for the year (+39%). Development/Small Scale Manufacturing revenue was $13.2 million in the quarter (+16%) and $56.2 million for the year (+24%). Large Scale Manufacturing revenue was $23.3 million in the quarter (+32%) and $81.5 million for the year (+7%). Royalties from Allegra in quarter were $6.8 million (+11%) and $28.3 million for the year (+5%). Milestone revenue from the company’s 2005 licensing agreement with Bristol-Myers Squibb was $5.5 million for the year, compared to $1.5 million in 2007.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters